Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations

Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of ap...

Full description

Bibliographic Details
Main Authors: Kazunori Toyoda, Hiroshi Yamagami, Masatoshi Koga
Format: Article
Language:English
Published: Korean Stroke Society 2018-09-01
Series:Journal of Stroke
Subjects:
Online Access:http://www.j-stroke.org/upload/pdf/jos-2018-01788.pdf
id doaj-c7d2d48118ce4e0f8d39055a372a1346
record_format Article
spelling doaj-c7d2d48118ce4e0f8d39055a372a13462020-11-25T03:39:27ZengKorean Stroke SocietyJournal of Stroke2287-63912287-64052018-09-0120332133110.5853/jos.2018.01788243Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other PopulationsKazunori Toyoda0Hiroshi Yamagami1Masatoshi Koga2 Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, Suita, Japan Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, JapanDevelopment of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of approval for clinical use of direct oral anticoagulants and idarucizumab, a specific reversal agent for dabigatran. A unique recommendation in the latest Japanese clinical guides was that thrombolysis can be recommended if the time of the last dose of direct oral anticoagulants exceeds 4 hours and if commonly available anticoagulation markers are normal or subnormal, i.e., international normalized ratio of prothrombin time <1.7 and activated partial thromboplastin time <1.5 times the baseline value (≤40 seconds only as a guide). These criteria are partly supported by the findings of domestic multicenter and single-center surveys that symptomatic or asymptomatic intracranial hemorrhage following thrombolysis was rare under the conditions of the criteria. Even for dabigatran users, stroke thrombolysis can be considered without pretreatment by idarucizumab if patients meet the above criteria. If not, direct mechanical thrombectomy can be considered without pretreatment by idarucizumab or thrombolysis, and use of idarucizumab, followed immediately by thrombolysis, can be considered only when thrombectomy cannot be quickly performed. These clinical guides are practical and to some extent economical, but they have some limitations, including lack of corroborating information from sufficient numbers of relevant cases. The guides will be further modified based on the results of future research.http://www.j-stroke.org/upload/pdf/jos-2018-01788.pdfguidestrokeanticoagulantsatrial fibrillationidarucizumabthrombolyic therapy
collection DOAJ
language English
format Article
sources DOAJ
author Kazunori Toyoda
Hiroshi Yamagami
Masatoshi Koga
spellingShingle Kazunori Toyoda
Hiroshi Yamagami
Masatoshi Koga
Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
Journal of Stroke
guide
stroke
anticoagulants
atrial fibrillation
idarucizumab
thrombolyic therapy
author_facet Kazunori Toyoda
Hiroshi Yamagami
Masatoshi Koga
author_sort Kazunori Toyoda
title Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
title_short Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
title_full Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
title_fullStr Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
title_full_unstemmed Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
title_sort consensus guides on stroke thrombolysis for anticoagulated patients from japan: application to other populations
publisher Korean Stroke Society
series Journal of Stroke
issn 2287-6391
2287-6405
publishDate 2018-09-01
description Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis. Officially authorized Japanese guidelines on this issue were revised twice at the time of approval for clinical use of direct oral anticoagulants and idarucizumab, a specific reversal agent for dabigatran. A unique recommendation in the latest Japanese clinical guides was that thrombolysis can be recommended if the time of the last dose of direct oral anticoagulants exceeds 4 hours and if commonly available anticoagulation markers are normal or subnormal, i.e., international normalized ratio of prothrombin time <1.7 and activated partial thromboplastin time <1.5 times the baseline value (≤40 seconds only as a guide). These criteria are partly supported by the findings of domestic multicenter and single-center surveys that symptomatic or asymptomatic intracranial hemorrhage following thrombolysis was rare under the conditions of the criteria. Even for dabigatran users, stroke thrombolysis can be considered without pretreatment by idarucizumab if patients meet the above criteria. If not, direct mechanical thrombectomy can be considered without pretreatment by idarucizumab or thrombolysis, and use of idarucizumab, followed immediately by thrombolysis, can be considered only when thrombectomy cannot be quickly performed. These clinical guides are practical and to some extent economical, but they have some limitations, including lack of corroborating information from sufficient numbers of relevant cases. The guides will be further modified based on the results of future research.
topic guide
stroke
anticoagulants
atrial fibrillation
idarucizumab
thrombolyic therapy
url http://www.j-stroke.org/upload/pdf/jos-2018-01788.pdf
work_keys_str_mv AT kazunoritoyoda consensusguidesonstrokethrombolysisforanticoagulatedpatientsfromjapanapplicationtootherpopulations
AT hiroshiyamagami consensusguidesonstrokethrombolysisforanticoagulatedpatientsfromjapanapplicationtootherpopulations
AT masatoshikoga consensusguidesonstrokethrombolysisforanticoagulatedpatientsfromjapanapplicationtootherpopulations
_version_ 1724538755368353792